2019
Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma
Department of Internal Medicine Y, Sutaria R, Patel P, Department of Rheumatology Y, Danve A. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. European Journal Of Rheumatology 2019, 6: 153-154. PMID: 30986169, PMCID: PMC6668642, DOI: 10.5152/eurjrheum.2019.18159.Peer-Reviewed Original ResearchMetastatic melanomaCheckpoint inhibitorsMyasthenia gravisAutoimmune myositisCombination of ipilimumabCytotoxic T lymphocytesCombination therapyT lymphocytesImmune responseAdverse effectsMelanomaNumerous immuneIpilimumabNivolumabNovel optionGravisMyositisDeactivation signalsInhibitorsMalignancyTherapyTumors
2015
The ongoing quest for biomarkers in Ankylosing Spondylitis
Danve A, O'Dell J. The ongoing quest for biomarkers in Ankylosing Spondylitis. International Journal Of Rheumatic Diseases 2015, 18: 826-834. PMID: 26469363, DOI: 10.1111/1756-185x.12779.Peer-Reviewed Original ResearchConceptsRadiographic progressionC-reactive proteinChronic inflammatory diseaseQuality of lifeDisease activityPotential clinical applicationsHLA-B27Ankylosing SpondylitisDiscovery of biomarkersInflammatory diseasesEarly diagnosisNew biomarkersSpondylitisBiomarkersDisease assessmentClinical applicationProgressionImmunopathogenesisTherapySymptomsDiseaseDiagnosis